TriangleNCT02162732 · OUTCOME
Days to Treatment Will be Used in Order to Determine Feasibility of Using Tumor Samples to Assess Genomic Sequencing Using Predictive Modeling to Make Real-time Treatment Decisions for Children With Relapsed/Refractory Cancers.
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- Days
- Interval / dispersion
- Full Range
- Time frame
- 2 years
What was measured
The definition of feasibility is: Enrollment onto study, genomic profile, analysis and report generation completed, tumor board held with treatment decision, treatment review completed, start of treatment, and completion of 1 cycle of therapy.
Groups in this outcome
Neuroblastoma
Subjects on study with a diagnosis of Neuroblastoma
CNS Tumors
Subjects on study with a diagnosis of a CNS Tumor which included, but was not limited to, Ependymoma, Glioblastoma, Diffuse Midline Glioma, and Other CNS Tumors.
Rare Tumors
Subjects on study with a diagnosis of a rare solid tumor which included, but was not limited to, Rhabdomyosarcoma, Ewing Sarcoma, Osteosarcoma, and Other Rare Tumors.
| Group | Source count |
|---|---|
| Neuroblastoma | 31 |
| CNS Tumors | 41 |
| Rare Tumors | 72 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Neuroblastoma | 31 | Not reported | 18 | 75 | Not reported |
| CNS Tumors | 48 | Not reported | 18 | 146 | Not reported |
| Rare Tumors | 35 | Not reported | 20 | 98 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 18
- upper Limit
- 75
- value
- 31
- group Id
- OG001
- lower Limit
- 18
- upper Limit
- 146
- value
- 48
- group Id
- OG002
- lower Limit
- 20
- upper Limit
- 98
- value
- 35
- denoms
- counts
- group Id
- OG000
- value
- 31
- group Id
- OG001
- value
- 41
- group Id
- OG002
- value
- 72
- units
- Participants
- description
- The definition of feasibility is: Enrollment onto study, genomic profile, analysis and report generation completed, tumor board held with treatment decision, treatment review completed, start of treatment, and completion of 1 cycle of therapy.
- dispersion Type
- Full Range
- groups
- description
- Subjects on study with a diagnosis of Neuroblastoma
- id
- OG000
- title
- Neuroblastoma
- description
- Subjects on study with a diagnosis of a CNS Tumor which included, but was not limited to, Ependymoma, Glioblastoma, Diffuse Midline Glioma, and Other CNS Tumors.
- id
- OG001
- title
- CNS Tumors
- description
- Subjects on study with a diagnosis of a rare solid tumor which included, but was not limited to, Rhabdomyosarcoma, Ewing Sarcoma, Osteosarcoma, and Other Rare Tumors.
- id
- OG002
- title
- Rare Tumors
- param Type
- MEAN
- reporting Status
- POSTED
- time Frame
- 2 years
- title
- Days to Treatment Will be Used in Order to Determine Feasibility of Using Tumor Samples to Assess Genomic Sequencing Using Predictive Modeling to Make Real-time Treatment Decisions for Children With Relapsed/Refractory Cancers.
- type
- PRIMARY
- unit Of Measure
- Days
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice